Raushan Kurmasheva, PhD, was awarded the Translation to Cure (T2C) Award by the CURE Childhood Cancer Foundation (https://curechildhoodcancer.org). Her project is titled: “Advancing Innovative and Effective Therapies for Children with Malignant Rhabdoid Tumors”. The research project presents a novel therapeutic strategy for malignant rhabdoid tumors (MRTs) by leveraging next-generation PARP1 inhibitors in combination with DNA-damaging agents. Given the unmet need for effective MRT treatments, particularly for infants, where radiotherapy is not a viable option, this approach has strong clinical translation potential. Our work will establish critical preclinical data to support future clinical trials, with the long-term goal of improving outcomes for children with these aggressive malignancies.